Tags

Type your tag names separated by a space and hit enter

Levodopa in the early treatment of Parkinson's disease.
Parkinsonism Relat Disord. 2009 Jan; 15 Suppl 1:S17-20.PR

Abstract

l-dopa has many advantages as initial therapy for Parkinson's disease (PD). It is safer, more efficacious, associated with fewer adverse effects, few interactions, easier for patients to use and for clinicians to prescribe, and cheaper than dopamine (DA) agonists. Although l-dopa is more likely than DA agonists to introduce motor fluctuations and dyskinesia, l-dopa is also more effective in improving motor function. Furthermore, there is no long-term benefit from delaying l-dopa based on the risk of motor complications or psychiatric symptoms. Many investigations have shown that l-dopa does not accelerate disease progression. Now is the time to re-evaluate l-dopa for initial treatment of PD.

Authors+Show Affiliations

Department of Neurology, National Center Hospital of Neurology & Psychiatry, Kodaira, Japan. mihom@ncnp.go.jp

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19131036

Citation

Murata, Miho. "Levodopa in the Early Treatment of Parkinson's Disease." Parkinsonism & Related Disorders, vol. 15 Suppl 1, 2009, pp. S17-20.
Murata M. Levodopa in the early treatment of Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 1:S17-20.
Murata, M. (2009). Levodopa in the early treatment of Parkinson's disease. Parkinsonism & Related Disorders, 15 Suppl 1, S17-20. https://doi.org/10.1016/S1353-8020(09)70006-9
Murata M. Levodopa in the Early Treatment of Parkinson's Disease. Parkinsonism Relat Disord. 2009;15 Suppl 1:S17-20. PubMed PMID: 19131036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa in the early treatment of Parkinson's disease. A1 - Murata,Miho, PY - 2009/1/10/entrez PY - 2009/3/14/pubmed PY - 2009/4/1/medline SP - S17 EP - 20 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 15 Suppl 1 N2 - l-dopa has many advantages as initial therapy for Parkinson's disease (PD). It is safer, more efficacious, associated with fewer adverse effects, few interactions, easier for patients to use and for clinicians to prescribe, and cheaper than dopamine (DA) agonists. Although l-dopa is more likely than DA agonists to introduce motor fluctuations and dyskinesia, l-dopa is also more effective in improving motor function. Furthermore, there is no long-term benefit from delaying l-dopa based on the risk of motor complications or psychiatric symptoms. Many investigations have shown that l-dopa does not accelerate disease progression. Now is the time to re-evaluate l-dopa for initial treatment of PD. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/19131036/Levodopa_in_the_early_treatment_of_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -